Lenvatinib (len) plus pembrolizumab (pembro) for advanced melanoma (MEL) that progressed on a PD-1 or PD-L1 inhibitor: Initial results of LEAP-004

被引：17

作者：

Arance Fernandez, A. M. ^{[1
]}

O'Day, S. J. ^{[2
]}

de la Cruz Merino, L. ^{[3
]}

Petrella, T. ^{[4
]}

Jamal, R. ^{[5
]}

Ny, L. ^{[6
,7
]}

Carneiro, A. ^{[8
,9
]}

Berrocal, A. ^{[10
]}

Marquez-Rodas, I. ^{[11
,12
]}

Spreafico, A. ^{[13
]}

Atkinson, V. Victoria ^{[14
]}

Svedman, F. Costa ^{[15
]}

Smith, A. D. ^{[16
]}

Chen, K. ^{[17
]}

Diede, S. J. ^{[17
]}

Krepler, C. ^{[17
]}

Long, G. V. ^{[18
,19
]}

机构：

[1] Hosp Clin Barcelona, Med Oncol, Melanoma Unit, Barcelona, Spain

[2] John Wayne Canc Inst, Med Oncol, Santa Monica, CA USA

[3] Hosp Univ Virgen Macarena, Dept Med, Seville, Spain

[4] Odette Canc Ctr, Sunnybrook Hlth Sci Ctr, Med Oncol, Toronto, ON, Canada

[5] Ctr Hosp Univ Montreal, Med, Montreal, PQ, Canada

[6] Univ Gothenburg, Oncol, Gothenburg, Sweden

[7] Sahlgrens Univ Hosp, Gothenburg, Sweden

[8] Skane Univ Hosp, Oncol & Radiat Phys, Lund, Sweden

[9] Lund Univ, Lund, Sweden

[10] Hosp Gen Univ Valencia, Med Oncol, Valencia, Spain

[11] Hosp Gen Univ Gregorio Maranon, Med Oncol, Madrid, Spain

[12] CIBERONC, Madrid, Spain

[13] Univ Toronto, Univ Hlth Network, Princess Margaret Canc Ctr, Med Oncol, Toronto, ON, Canada

[14] Univ Queensland, Princess Alexandra Hosp, Dermatol, Brisbane, Qld, Australia

[15] Karolinska Univ Hosp, Dept Oncol, Stockholm, Sweden

[16] Eisai Ltd, Clin Res, Hatfield, Herts, England

[17] Merck & Co Inc, Clin Res, Kenilworth, NJ USA

[18] Univ Sydney, Melanoma Inst Australia, Sydney, NSW, Australia

[19] Royal North Shore & Mater Hosp, Sydney, NSW, Australia

来源：

ANNALS OF ONCOLOGY | 2020年 / 31卷

关键词：

D O I：

10.1016/j.annonc.2020.08.2274

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

LBA44

引用

页码：S1173 / S1173

页数：1